comparemela.com

Latest Breaking News On - Cancer immunology at oslo university hospital - Page 1 : comparemela.com

Oncopeptides : publishes article on NK cell engagers in New Biotechnology -Today at 07:08 am

September 12, 2023 A new article, describing a set of affibody-based NK cell engagers using B cell maturation antigen as a model antigen for targeting of.

Finland
Stockholm
Sweden
Norway
Oslo
David-augustsson
Cancer-immunology-at-oslo-university-hospital
Corporate-affairs
European-federation-of-biotechnology
Pharmatest-services-ltd-in-turku
Royal-institute-of-technology
Sweden-innovation-agency

Oncopeptides AB: Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

STOCKHOLM, Sept. 7, 2022 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological

United-kingdom
Germany
Norway
Stockholm
Sweden
Italy
Finland
Oslo
France
Spain
Fredrik-schjesvold
Rolf-gulliksen

Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for.

United-kingdom
Germany
Norway
Stockholm
Sweden
Italy
Finland
Oslo
France
Spain
Fredrik-schjesvold
Rolf-gulliksen

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.